Mineralys Therapeutics, Inc. Common Stock logo

Mineralys Therapeutics, Inc. Common Stock(MLYS)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$13.66
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for MLYS

11/20/2026: MLYS (1-star) is currently NOT-A-BUY. Pass it for now.

Mineralys Therapeutics is a clinical-stage biopharmaceutical company advancing its lead candidate, lorundrostat, an aldosterone synthase inhibitor targeting uncontrolled and resistant hypertension. The company's primary strength lies in its positive late-stage clinical data demonstrating robust blood pressure reductions without impairing cortisol synthesis. Its main investment story centers on an upcoming regulatory decision and potential commercialization path in a multi-billion-dollar cardiorenal market. However, primary risks include single-asset pipeline dependency, intense competition from established pharmaceutical alternatives, and the execution challenges of transitioning into a commercial enterprise. The stock suits growth-oriented biotech investors willing to accept high regulatory volatility while monitoring pivotal commercial milestones.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe company offers high-growth potential anchored by a near-term commercial product launch and clinical expansion opportunities.
Momentum investorStrong fit while signal remains positiveStock price movement is highly sensitive to regulatory milestones and clinical catalysts, creating short-term momentum opportunities.
Value investorWeak fitThe lack of current product revenues and earnings makes traditional valuation metrics inapplicable at this stage.
Dividend investorWeak fitAs a clinical-stage biotechnology company, Mineralys does not pay dividends.
Low-risk investorWeak fitHigh clinical, regulatory, and financial volatility make this stock unsuitable for conservative, low-risk capital.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighClinical-stage biotechnology stocks frequently experience sharp price swings driven by binary regulatory and trial outcomes.
Valuation riskHighValuation is entirely speculative based on future commercial forecasts rather than historical sales or earnings.
Competition risk (aldosterone inhibitors and multi-drug regimens)HighCompeting against established pharma players with approved alternatives poses significant market adoption hurdles.
Business qualityMediumWhile the scientific mechanism is validated, the company lacks a diversified commercial portfolio.
Dividend incomeLow / noneNo dividends are paid or expected in the near term as all capital is reinvested into clinical and commercial operations.
Execution riskHighTransitioning from a clinical developer to a commercial-stage pharmaceutical seller involves immense execution challenges.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.25B USD
Price to earnings Ratio -
1Y Target Price 43.56
Price to earnings Ratio -
1Y Target Price 43.56
Volume (30-day avg) 1.8M shares
Beta 0.82
52 Weeks Range 13.57 - 44.13
Updated Date 11/19/2026
52 Weeks Range 13.57 - 44.13
Updated Date 11/19/2026
Dividends yield (FY) -
Basic EPS (TTM) -4.3

Sector & Industry Intelligence

Sector

Healthcare

Constructive
Sentiment
Strong Bullish
Momentum
BUY Breadth Improving
BUY participation
55.2%
Active BUY / eligible
53 / 96
30-Day BUY Count Change
+19
Market state
Strong Bullish

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Biotechnology

BUY participation
43.2%
Active BUY / eligible
19 / 44
30-Day BUY Count Change
+12

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit 10.2%
Avg. Invested days 27
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 2.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
MLYS receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
MLYS has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, solid earnings growth (+13.0%) is partially offset by soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%), soft profitability (net margin 0.0%).

Financial Health Rating

★★★★★
MLYS's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is MLYS's strongest growth driver at +14.4% FY2025 versus FY2024 (solid, 4 stars). By comparison, earnings growth (+13.0%, solid) is also solid, while revenue growth (+0.0%, slightly negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 113.3% and approximately 75.4% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership is only 0.73%, which materially reduces the ownership score.

Top 5 Institutional Investors

Catalys Pacific LLC 8.81%
RA Capital Management, LLC 8.69%
BlackRock Inc 6.65%
Samsara BioCapital, LLC 6.63%
FMR Inc 5.09%

Unit Economics (Per $1K Revenue)

★★★★★
MLYS generates approximately $-0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
MLYS has a liquid profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Small / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Cardiorenal Therapeutics (Pre-commercial)Future sales of lorundrostat for uncontrolled and resistant hypertension and potential label expansions in chronic kidney disease.The company currently generates zero revenue and relies entirely on future drug approvals to establish its business model.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 695.69M
Price to Sales(TTM) -
Enterprise Value 695.69M
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -7.41
Shares Outstanding 88.56M
Shares Floating 66.75M
Shares Outstanding 88.56M
Shares Floating 66.75M
Percent Insiders 0.73
Percent Institutions 113.31

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.